ConductScience.org, home

Paper15922945

The 'danger' sensors that STOP the immune response: the A2 adenosine receptors?

Sitkovsky MV and 1 other. Trends Immunol, 2005. Cited by 211 papers, by iCite.

Cite this record

ConductScience Library. The 'danger' sensors that STOP the immune response: the A2 adenosine receptors? Papers, record 15922945. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/15922945

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The 'danger' sensors that STOP the immune response: the A2 adenosine receptors?
PubMed
Journal
Trends Immunol
PubMed
Year
2005
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
211
iCite
Relative citation ratio, by iCite
4.42
iCite
Revised in PubMed
2026-01-30
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Sitkovsky MVMichail V
2Ohta AAkio

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
ImmunityMajor topic
Receptors, Adenosine A2Major topic
Adenosine
Animals
Humans
Inflammation
Time Factors

Source PubMed

Download CSV of topics

Cited by138

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 211 citations.

PMIDTitleJournalYearIn PapersSource
42656532Chronic TLR7 activation promotes expansion of activated CD11c+ double-negative B cells and autoreactive humoral responses in lupus-like autoimmunity.Front Immunol2026https://conductscience.org/library/papers/42656532PubMed
42543247Adenosine Receptor 3 Antagonism Suppresses Adipogenesis via the EREG-EGFR-Leptin Axis in Multipotent Cells.Biofactors2026https://conductscience.org/library/papers/42543247PubMed
41596443Constitutively Active Stat5b Expression in Dendritic Cells Enhances Treg-Mediated Elimination of Autoreactive CD8+ T Cells in Autoimmune Diabetes.Int J Mol Sci2026https://conductscience.org/library/papers/41596443PubMed
40303336Nanomaterials-mediated adenosine pathway inhibition for strengthening cancer immunotherapy.Theranostics2025https://conductscience.org/library/papers/40303336PubMed
39329710Treg Cell Therapeutic Strategies for Breast Cancer: Holistic to Local Aspects.Cells2024https://conductscience.org/library/papers/39329710PubMed
39072327Regulatory T cell homing and activation is a signature of neonatal sepsis.Front Immunol2024https://conductscience.org/library/papers/39072327PubMed
38799466Glycan-based scaffolds and nanoparticles as drug delivery system in cancer therapy.Front Immunol2024https://conductscience.org/library/papers/38799466PubMed
38500877Metabolic instruction of the graft-versus-leukemia immunity.Front Immunol2024https://conductscience.org/library/papers/38500877PubMed
38200005Prostaglandin E2 controls the metabolic adaptation of T cells to the intestinal microenvironment.Nat Commun2024https://conductscience.org/library/papers/38200005PubMed
38039267Can antibody conjugated nanomicelles alter the prospect of antibody targeted therapy against schistosomiasis mansoni?PLoS Negl Trop Dis2023https://conductscience.org/library/papers/38039267PubMed
38018576Cell-based therapies for the treatment of rheumatoid arthritis.Immun Inflamm Dis2023https://conductscience.org/library/papers/38018576PubMed
37897562Metabolic interventions combined with CTLA-4 and PD-1/PD-L1 blockade for the treatment of tumors: mechanisms and strategies.Front Med2023https://conductscience.org/library/papers/37897562PubMed
37892114The Role of Adenosine in γδ T-Cell Regulation of Th17 Responses in Experimental Autoimmune Uveitis.Biomolecules2023https://conductscience.org/library/papers/37892114PubMed
37891562Caffeine-folic acid-loaded-chitosan nanoparticles combined with methotrexate as a novel HepG2 immunotherapy targeting adenosine A2A receptor downstream cascade.BMC Complement Med Ther2023https://conductscience.org/library/papers/37891562PubMed
37843749Pharmacological interaction and immune response of purinergic receptors in therapeutic modulation.Purinergic Signal2024https://conductscience.org/library/papers/37843749PubMed
37576576Immune and inflammatory mechanism of remote ischemic conditioning: A narrative review.Brain Circ2023https://conductscience.org/library/papers/37576576PubMed
36267157Transforming growth factor-β in tumour development.Front Mol Biosci2022https://conductscience.org/library/papers/36267157PubMed
36182536Schistosoma mansoni and the purinergic halo.Trends Parasitol2022https://conductscience.org/library/papers/36182536PubMed
35498376Remote Conditioning by Rhythmic Compression of Limbs Ameliorated Myocardial Infarction by Downregulation of Inflammation via A2 Adenosine Receptors.Front Cardiovasc Med2021https://conductscience.org/library/papers/35498376PubMed
34969052Schistosome immunomodulators.PLoS Pathog2021https://conductscience.org/library/papers/34969052PubMed

See all 138 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/15922945

GET https://conductscience.org/api/papers/v1/15922945/cited_by?page=2